Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
Overview
Neurology
Authors
Affiliations
The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.
Homocysteine and Age-Related Central Nervous System Diseases: Role of Inflammation.
Tawfik A, Elsherbiny N, Zaidi Y, Rajpurohit P Int J Mol Sci. 2021; 22(12).
PMID: 34200792 PMC: 8230490. DOI: 10.3390/ijms22126259.
A Population Perspective on Prevention of Dementia.
Eggink E, Moll van Charante E, van Gool W, Richard E J Clin Med. 2019; 8(6).
PMID: 31212802 PMC: 6617301. DOI: 10.3390/jcm8060834.
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.
Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues J J Prev Alzheimers Dis. 2015; 1(1):13-22.
PMID: 26594639 PMC: 4652787.
Grill J, Bateman R, Buckles V, Oliver A, Morris J, Masters C Alzheimers Res Ther. 2015; 7(1):50.
PMID: 26203303 PMC: 4511231. DOI: 10.1186/s13195-015-0135-0.
Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
Coley N, Gallini A, Andrieu S CNS Drugs. 2015; 29(7):519-28.
PMID: 26188654 DOI: 10.1007/s40263-015-0256-9.